Jefferies Would Still Buy Dynavax Technologies (DVAX) if CRL Issued Friday
Tweet Send to a Friend
Jefferies reiterated ts Buy rating and $5 price target on Dynavax Technologies (NASDAQ: DVAX) ahead of Friday's Heplisav FDA decision.
This article: 133 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 133 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
